All News
Autoimmune Disease Augments Cardiovascular Risk
A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.
Read ArticleInfluenza Vaccination Recommendations
The CDC has published an update to the recommendations from the Advisory Committee on Immunization Practices (ACIP) on the use of seasonal influenza vaccines in the United States for the 2022-23 season.
Read ArticleOlokizumab, another IL-6 Inhibitor for RA
This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets IL-6 in patients with rheumatoid arthritis.
This is in contrast to two other marketed IL-6 inhibitors (sarilumab, tocilizumab) that bind to the IL-6 receptor.
Bullous Systemic Lupus Erythematosus
Bullous systemic lupus erythematosus (BSLE) is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).
As goes SLE, bullous disease typically affects women, especially those of African descent.
Read ArticleManaging JDM with Calcinosis
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.
Read ArticleLow Dose IL-2 Therapy in SLE
A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE).
Read ArticleLess Organ Damage with Remission in SLE
A cohort study of SLE patients shows that remission and low disease activity (LDA) are associated with less damage accrual over time.
Read ArticleUtility of Repeat ENA Antibody Testing
Repeat serologic testing is not uncommon, but is it warranted? A retrospective study shows that repeated testing for autoantibodies to extractable nuclear antigens (ENA) rarely changes the result or adds a new diagnosis.
Read ArticleCDC Reviews Monkeypox
MMWR recently reviewed the epidemiology and characteristics of U.S. monkeypox cases seen between May and July 2022.
Read ArticleMore Bad Safety News for Xeljanz
Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in rheumatoid arthritis are higher than with tumor necrosis factor (TNF) inhibitors.
Read ArticleACR Updated Guideline on Vaccinations for Rheumatic Patients
The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).
Read ArticleThe Approach to Difficult to Treat Rheumatoid Arthritis
Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.
Read ArticlePlasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus
Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. When administered to patients with cutaneous lupus erythematosus (CLE) was shown reducing disease activity in CLE patients.
Read ArticleApproach to ILD in Myositis Syndromes
Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.
Read ArticleRheumatic Causes for Fever of Unknown Origin
Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.
Read ArticleMitochondria as Master Regulators of Inflammation
Mitochondrial constituents and metabolic products may give rise to immune activation; this is especially true for mitochondrial DNA, which can function as damage-associated molecular patterns (DAMPs) leading to inflammasome activation.
Read ArticleEarly, Aggressive and Seropositive (7.22.2022)
Dr. Jack Cush covers the news and journal reports from the past week on RheumNow.com. This week we have Insights NAFLD, overdose deaths, septic arthritis, refractory stills, & when MTX doesn’t work.
Read ArticleMRP8/14 as a Biomarker in Systemic Juvenile Idiopathic Arthritis
A large cohort study of children with febrile disorders has demonstrated the diagnostic utility of Myeloid-related protein 8/14 (MRP8/14) in diagnosing systemic JIA patients (SJIA) in clinical practice.
Read ArticleMTX + Pegloticase Combo FDA Approved
Horizon has announced that the U.S. Food and Drug Administration (FDA) has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout.
Read ArticleICYMI: 2021 Rheumatology Year in Review
For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read Article